加载中
Viridian Therapeutics, Inc. is a biotechnology firm committed to creating therapies for patients afflicted by serious illnesses. Its primary development efforts include VRDN-001, a humanized monoclonal anti-IGF-1R antibody currently advancing through Phase 1/2 clinical trials for thyroid eye disease (TED). The company's portfolio also features VRDN-002, an IGF-1R antibody undergoing Phase 1 clinical evaluation, alongside VRDN-003, a therapeutic antibody also designed to target IGF-1R for TED. Established in 2006, this Waltham, Massachusetts-based firm previously operated as Miragen Therapeutics, Inc., before changing its name to Viridian Therapeutics, Inc. in January 2021.
前收盘价
US$18.30
−US$0.36 · -1.93%
盘后
US$18.30
US$0.00 · 0.00%
10月12日 19:30 ET
盘中时间采用ET。市场数据可能有所延迟。
Viridian Therapeutics, Inc. is a biotechnology firm committed to creating therapies for patients afflicted by serious illnesses. Its primary development efforts include VRDN-001, a humanized monoclonal anti-IGF-1R antibody currently advancing through Phase 1/2 clinical trials for thyroid eye disease (TED). The company's portfolio also features VRDN-002, an IGF-1R antibody undergoing Phase 1 clinical evaluation, alongside VRDN-003, a therapeutic antibody also designed to target IGF-1R for TED. Established in 2006, this Waltham, Massachusetts-based firm previously operated as Miragen Therapeutics, Inc., before changing its name to Viridian Therapeutics, Inc. in January 2021.
日内区间
当前US$18.30
52周区间
当前US$18.30
盘中时间采用ET。市场数据可能有所延迟。
Viridian Therapeutics, Inc. is a biotechnology firm committed to creating therapies for patients afflicted by serious illnesses. Its primary development efforts include VRDN-001, a humanized monoclonal anti-IGF-1R antibody currently advancing through Phase 1/2 clinical trials for thyroid eye disease (TED). The company's portfolio also features VRDN-002, an IGF-1R antibody undergoing Phase 1 clinical evaluation, alongside VRDN-003, a therapeutic antibody also designed to target IGF-1R for TED. Established in 2006, this Waltham, Massachusetts-based firm previously operated as Miragen Therapeutics, Inc., before changing its name to Viridian Therapeutics, Inc. in January 2021.
日内区间
当前US$18.30
52周区间
当前US$18.30
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 7084.9万 USD | 30.2万 USD | 31.4万 USD | 177.2万 USD | 296.3万 USD |
| 毛利 | 7084.9万 USD | 30.2万 USD | 31.4万 USD | 177.2万 USD | 296.3万 USD |
| 研究与开发 | 3.39亿 USD | 2.38亿 USD | 1.6亿 USD | 1.01亿 USD | 5688.6万 USD |
| 销售、一般及管理费用 | 9531.5万 USD | 6108.3万 USD | 9499.9万 USD | 3518.2万 USD | 2580.5万 USD |
| 营业费用 | 4.34亿 USD | 2.99亿 USD | 2.55亿 USD | 1.36亿 USD | 8269.1万 USD |
| 利息收入 | 2739.9万 USD | 3213.2万 USD | 1856.3万 USD | 491.6万 USD | 31.8万 USD |
| 利息支出 | 494.8万 USD | 304.6万 USD | 184.7万 USD | 48.6万 USD | 3000 USD |
| 折旧和摊销 | 46万 USD | 54万 USD | 52.2万 USD | 25.5万 USD | 12万 USD |
| 营业利润 | −3.63亿 USD | −2.99亿 USD | −2.54亿 USD | −1.34亿 USD | −7972.8万 USD |
| 净利润 | −3.43亿 USD | −2.7亿 USD | −2.38亿 USD | −1.3亿 USD | −7941.3万 USD |
公司数据更新于 2026年10月13日。
已公布业绩及可用的市场共识预期。
已公布业绩及可用的市场共识预期。
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$36.43
上涨空间 99.07%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI7755.61万0.00%2.3万亿 USD0.03%US$381.57-0.10%
iShares Russell 2000 ETFIWM4873.96万0.06%787.4亿 USD0.19%US$277.9-0.37%
State Street SPDR S&P Biotech ETFXBI4584.59万0.46%103.03亿 USD0.35%US$151.4-1.54%
Vanguard Extended Market ETFVXF2645.97万0.03%954亿 USD0.05%US$233.52-0.63%
Dimensional - US Small Cap ETFDFAS1307.19万0.04%338.04亿 USD0.31%US$78.17-0.23%
Vanguard Russell 2000 ETFVTWO1201.85万0.07%180亿 USD0.06%US$112.27-0.35%
Schwab U.S. Small-Cap ETFSCHA1092.22万0.05%217.13亿 USD0.03%US$32.66-0.40%
iShares Micro-Cap ETFIWC591.06万0.45%13.17亿 USD0.60%US$181.66-0.73%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIVanguard Extended Market ETFVXFDimensional - US Small Cap ETFDFASVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAiShares Micro-Cap ETFIWCAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
